Relmada TherapeuticsRLMD
Market Cap: $106M
About: Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
Employees: 20
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
183% more call options, than puts
Call options by funds: $568K | Put options by funds: $201K
2.89% less ownership
Funds ownership: 47.83% [Q1] → 44.93% (-2.89%) [Q2]
14% less funds holding
Funds holding: 92 [Q1] → 79 (-13) [Q2]
39% less capital invested
Capital invested by funds: $67.1M [Q1] → $40.7M (-$26.4M) [Q2]
52% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 31
68% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 19
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Jefferies Andrew Tsai 25% 1-year accuracy 1 / 4 met price target | 271%upside $13 | Buy Upgraded | 17 Sept 2024 |